Explore more about: Point of Care

In recognition of International Women’s Day (March 8), we’re featuring Rebecca Richards-Kortum, Ph.D., a longtime bioengineer in academia who has contributed globally to improving women's health.

NIH announced finalists in its competition to accelerate development of diagnostic and monitoring technologies to improve fetal health outcomes in low-resource settings.

A new RADx Tech fellowship aims to increase diversity among biotechnology innovators. Fellows who recently completed the six-month program share their perspectives on how the fellowship helped them advance their technologies.

Emory University announced on Wednesday that the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health has awarded a team of academic and medical institutions — including Emory University, the Georgia Institute of Technology and Children’s Healthcare of Atlanta — $7.8 million for research. Source: The Atlanta Journal-Constitution

UMass Chan Medical School and UMass Lowell have received $8.9 million from the National Institutes of Health in support for their development of home care technology. Source: Worcester Business Journal

NIH will advance the development of home-based and point-of-care health technologies with awards to six technology research and development centers around the country. The centers comprise the Point of Care Technology Research Network (POCTRN) and will parlay the momentum of the original network established in 2007 by the NIBIB.

New recommendations from the NIH Rapid Acceleration of Diagnostics (RADx®) Tech Program provide a blueprint for the design and manufacture of more accessible diagnostic tests.

One day, the ultrasound equipment that health care professionals use for essential diagnostic imaging may no longer be confined to the clinic, instead operated by patients in the comfort of their homes. New research marks a major step toward that future.

A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.